In this study, both TGF-β and PD-1 were targeted using galunisertib in combination with nivolumab in patients with advanced refractory solid tumors and in patients with recurrent/refractory NSCLC who were PD-(L)1 naïve. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.